The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.

  • cardfireEnglish
    3·
    14 hours ago

    Doubtful. Even one of me is pretty lazy. They’ll want someone more apt for their clone army.